{"id":67034,"date":"2026-05-15T17:41:34","date_gmt":"2026-05-15T12:11:34","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=67034"},"modified":"2026-05-15T17:41:37","modified_gmt":"2026-05-15T12:11:37","slug":"coronary-no-reflow-phenomenon","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/","title":{"rendered":"Coronary No-Reflow Phenomenon"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/eoe6CLHCpH0?si=aOdWy1Dq9NKoLhwE\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">The <strong>coronary no-reflow phenomenon<\/strong> is a clinical condition characterized by inadequate myocardial perfusion through a given segment of the coronary circulation without evidence of mechanical obstruction in the epicardial vessel. It is most frequently encountered during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pathophysiology<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The etiology is multifactorial and often described as a combination of four distinct processes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Distal Embolization:<\/strong> Migration of plaque fragments, fibrin, and platelet aggregates from the culprit lesion into the microvasculature during balloon inflation or stent deployment.<\/li>\n\n\n\n<li class=\"\"><strong>Ischemia-Reperfusion Injury:<\/strong> Damage caused by the sudden restoration of blood flow, leading to the production of reactive oxygen species (ROS), calcium overload, and the opening of the mitochondrial permeability transition pore (mPTP).<\/li>\n\n\n\n<li class=\"\"><strong>Microvascular Damage:<\/strong> Structural injury to the endothelial cells, resulting in blebbing, swelling, and reduced vessel lumen. This is often exacerbated by neutrophil infiltration and &#8220;capillary plugging.&#8221;<\/li>\n\n\n\n<li class=\"\"><strong>Individual Susceptibility:<\/strong> Predisposing factors such as hypercholesterolemia, diabetes, and the duration of pre-hospital ischemia.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical Diagnosis<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">No-reflow is typically identified in the cardiac catheterization lab using the following criteria:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">1. Angiographic Indicators<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>TIMI Flow Grade:<\/strong> A grade of 0, 1, or 2 despite the absence of an epicardial dissection, spasm, or residual stenosis.<\/li>\n\n\n\n<li class=\"\"><strong>Myocardial Blush Grade (MBG):<\/strong> A qualitative assessment of myocardial opacification. MBG 0 or 1 indicates significant microvascular obstruction.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">2. Electrocardiographic (ECG) Findings<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>ST-Segment Resolution (STR):<\/strong> Failure of the ST-segment to resolve by >70% within 60\u201390 minutes post-reperfusion suggests impaired microvascular flow.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">3. Advanced Imaging<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Cardiac MRI:<\/strong> Considered the gold standard for identifying <strong>Microvascular Obstruction (MVO)<\/strong>, visualized as a dark &#8220;hypo-enhanced&#8221; core within the hyper-enhanced infarcted area on Late Gadolinium Enhancement (LGE) images.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Management Strategies<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Pharmacological Interventions<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Intracoronary (IC) administration is generally preferred over intravenous routes to achieve higher local concentrations:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Adenosine:<\/strong> A potent vasodilator that acts on A<sub>2<\/sub> receptors to reduce microvascular resistance.<\/li>\n\n\n\n<li class=\"\"><strong>Verapamil\/Diltiazem:<\/strong> Effective in reducing microvascular spasm.<\/li>\n\n\n\n<li class=\"\"><strong>Nitroprusside:<\/strong> An endothelium-independent vasodilator and nitric oxide donor.<\/li>\n\n\n\n<li class=\"\"><strong>Nicardipine:<\/strong> Often used due to its high selectivity for arterial smooth muscle.<\/li>\n\n\n\n<li class=\"\"><strong>GP IIb\/IIIa Inhibitors:<\/strong> Such as Abciximab or Tirofiban to address the thrombotic component.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Mechanical Interventions<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Aspiration Thrombectomy:<\/strong> While once routine, <a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001309#sec-10-2\" type=\"link\" id=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001309#sec-10-2\">current guidelines do not recommend routine manual thrombectomy<\/a>, though it may be considered in cases of high thrombus burden.<\/li>\n\n\n\n<li class=\"\"><strong>Distal Protection Devices:<\/strong> Primarily used in saphenous vein graft (SVG) interventions to capture embolic debris, though they have shown limited benefit in native coronary arteries during STEMI.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Prognostic Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The occurrence of no-reflow is a strong independent predictor of adverse outcomes. It is associated with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\">Increased infarct size.<\/li>\n\n\n\n<li class=\"\">Reduced Left Ventricular Ejection Fraction (LVEF).<\/li>\n\n\n\n<li class=\"\">Higher rates of malignant arrhythmias and heart failure.<\/li>\n\n\n\n<li class=\"\">Increased short- and long-term mortality.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Comparative efficacy of IC vs. IV pharmacological agents<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While the IC route offers a physiological advantage by achieving higher local drug concentrations and greater receptor occupancy at the microvascular level, large-scale evidence for clinical endpoint superiority remains nuanced across different drug classes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Comparative Efficacy by Drug Class<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">1. Vasodilators (Epinephrine, Verapamil, Adenosine)<sup><\/sup><\/h3>\n\n\n\n<p id=\"p-rc_0e979c938ec494cc-25\" class=\"wp-block-paragraph\">Recent network meta-analyses have shifted the preference toward IC epinephrine and verapamil for acute flow restoration:<sup><\/sup><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>IC Epinephrine vs. IC Adenosine:<\/strong> The <strong><a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCINTERVENTIONS.121.011408\" type=\"link\" id=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCINTERVENTIONS.121.011408\">COAR trial<\/a><\/strong> and subsequent meta-analyses demonstrated that IC epinephrine is significantly more effective than IC adenosine in achieving final <strong>TIMI 3 flow<\/strong> in normotensive patients.<\/li>\n\n\n\n<li class=\"\"><strong>Direct Efficacy:<\/strong> A 2025 network meta-analysis of 1,674 patients found that <strong>IC epinephrine<\/strong> (OR: 2.81) and <strong>IC verapamil<\/strong> (OR: 2.84) were associated with significantly higher odds of achieving TIMI 3 flow compared to control groups (<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12955103\/\" type=\"link\" id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12955103\/\">Oliveri et al., 2026<\/a>).<\/li>\n\n\n\n<li class=\"\"><strong>ST-Resolution:<\/strong> While IC adenosine remains effective for improving <strong>ST-segment resolution<\/strong> (STR), its efficacy in restoring epicardial TIMI flow appears lower than that of epinephrine or verapamil  (<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12955103\/\" type=\"link\" id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12955103\/\">Oliveri et al., 2026<\/a>).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">2. Glycoprotein IIb\/IIIa Inhibitors (GPIs)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The route of administration for GPIs remains a point of clinical debate, with a focus on local thrombus resolution:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>IC vs. IV Abciximab:<\/strong> Pooled individual patient data from randomized trials indicate that IC abciximab does <strong>not<\/strong> significantly improve TIMI 3 flow or 30-day mortality compared to the IV route. However, it does significantly improve <strong>Myocardial Blush Grade (MBG 2\/3)<\/strong> (<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24457282\/\" type=\"link\" id=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24457282\/\">Piccolo et al., 2014<\/a>).<\/li>\n\n\n\n<li class=\"\"><strong>IC Tirofiban:<\/strong> A 2026 randomized controlled study found that IC tirofiban significantly reduced the incidence of no-reflow (20% vs. 53%) and decreased <strong>in-hospital MACE<\/strong> (3.33% vs. 30%) compared to placebo, though it increased minor bleeding risk (<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12978383\/\" type=\"link\" id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12978383\/\">Hammad et al., 2026<\/a>).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">3. Fibrinolytics (Low-Dose)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The use of IC fibrinolytics is emerging as a niche strategy for dissolving microvascular thrombi that vasodilators cannot address:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Current Status:<\/strong> Evidence suggests that selectively delivering approximately <strong>20% of the systemic dose<\/strong> of a fibrinolytic (e.g., alteplase, prourokinase) via the IC route before PCI may ameliorate the burden of microvascular thrombus (<a href=\"https:\/\/eurointervention.pcronline.com\/article\/low-dose-fibrinolysis-during-primary-percutaneous-intervention-for-preventing-no-reflow-stepping-back-to-move-forward\" type=\"link\" id=\"https:\/\/eurointervention.pcronline.com\/article\/low-dose-fibrinolysis-during-primary-percutaneous-intervention-for-preventing-no-reflow-stepping-back-to-move-forward\">Pelliccia &amp; Niccoli, 2022<\/a>).<\/li>\n\n\n\n<li class=\"\"><strong>Recent Evidence:<\/strong> The <strong><a href=\"https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2020.01.041\" type=\"link\" id=\"https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2020.01.041\">T-TIME trial<\/a><\/strong> (2020) showed no benefit for unselected STEMI patients. In patients presenting with ST-segment elevation myocardial infarction and an ischemic time \u22654 to 6 h, adjunctive treatment with low-dose intracoronary alteplase during primary percutaneous coronary intervention was associated with increased microvascular obstruction. Intracoronary alteplase may be harmful for this subgroup.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Summary of IC vs. IV Advantages<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Feature<\/strong><\/td><td><strong>Intracoronary (IC)<\/strong><\/td><td><strong>Intravenous (IV)<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Local Concentration<\/strong><\/td><td>Extremely High (10-100 times systemic)<\/td><td>Moderate\/Systemic<\/td><\/tr><tr><td><strong>Onset of Action<\/strong><\/td><td>Immediate at the target site<\/td><td>Delayed by circulation time<\/td><\/tr><tr><td><strong>Systemic Side Effects<\/strong><\/td><td>Potential for local arrhythmias (Epi)<\/td><td>Hypotension (Nitroprusside\/Adenosine)<\/td><\/tr><tr><td><strong>Clinical Verdict<\/strong><\/td><td>Preferred for acute laboratory rescue<\/td><td>Preferred for upstream &#8220;cooling&#8221; of lesions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Ongoing trials such as the <strong><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04573751\" type=\"link\" id=\"https:\/\/clinicaltrials.gov\/study\/NCT04573751\">EPIVER study<\/a><\/strong> (comparing the combination of IC epinephrine and verapamil against monotherapy), are expected to provide further clarity on standardized pharmacological &#8220;cocktails&#8221; for refractory cases.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">References<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Brugaletta, S. (2026). Slow flow and no reflow after percutaneous coronary intervention. <em>EuroIntervention<\/em>. <a href=\"https:\/\/eurointervention.pcronline.com\/article\/slow-flow-and-no-reflow-after-percutaneous-coronary-intervention\">https:\/\/eurointervention.pcronline.com\/article\/slow-flow-and-no-reflow-after-percutaneous-coronary-intervention<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dil, S. V. (2025). <a href=\"https:\/\/cardiovascular.elpub.ru\/jour\/article\/view\/2936\/0?locale=en_US\" type=\"link\" id=\"https:\/\/cardiovascular.elpub.ru\/jour\/article\/view\/2936\/0?locale=en_US\">Intracoronary epinephrine and verapamil in the refractory no-reflow phenomenon in patients with acute myocardial infarction<\/a>. <em>Cardiovascular Therapy and Prevention<\/em>. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hammad, M. A. M. (2026). Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Vessel. <em>PMC<\/em>. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12978383\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12978383\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Oliveri, F. (2026). Intracoronary Vasoactive Therapy for No-Reflow During Primary PCI: A Network Meta-Analysis of Randomized Trials. <em>PMC<\/em>. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12955103\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12955103\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pelliccia, F., &amp; Niccoli, G. (2022). Low-dose fibrinolysis during primary percutaneous intervention for preventing no-reflow: stepping back to move forward? <em>EuroIntervention<\/em>, <em>18<\/em>(6), 452-455. <a href=\"https:\/\/doi.org\/10.4244\/eij-d-22-00250\">https:\/\/doi.org\/10.4244\/eij-d-22-00250<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Piccolo, R., Eitel, I., Iversen, A. Z., Gu, Y. L., Dominguez-Rodriguez, A., de Smet, B. J. G. L., Mahmoud, K. D., Abreu-Gonzalez, P., Thiele, H., &amp; Piscione, F. (2014). <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24457282\/\" type=\"link\" id=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24457282\/\">Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.<\/a> <em>EuroIntervention<\/em>, <em>9<\/em>(9), 1110-1120. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rao, S. V. (2025). 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. <em>Circulation<\/em>. <a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001309\">https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001309<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The coronary no-reflow phenomenon is a clinical condition characterized by inadequate myocardial perfusion through a given segment of the coronary circulation without evidence of mechanical obstruction in the epicardial vessel. It is most frequently encountered during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Pathophysiology The etiology is multifactorial and often described [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":67036,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-67034","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Coronary No-Reflow Phenomenon - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Coronary No-Reflow Phenomenon - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"The coronary no-reflow phenomenon is a clinical condition characterized by inadequate myocardial perfusion through a given segment of the coronary circulation without evidence of mechanical obstruction in the epicardial vessel. It is most frequently encountered during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Pathophysiology The etiology is multifactorial and often described [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T12:11:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-15T12:11:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/05\/Coronary-No-Reflow-Phenomenon.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1202\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Coronary No-Reflow Phenomenon\",\"datePublished\":\"2026-05-15T12:11:34+00:00\",\"dateModified\":\"2026-05-15T12:11:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/\"},\"wordCount\":1082,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Coronary-No-Reflow-Phenomenon.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/\",\"name\":\"Coronary No-Reflow Phenomenon - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Coronary-No-Reflow-Phenomenon.jpg\",\"datePublished\":\"2026-05-15T12:11:34+00:00\",\"dateModified\":\"2026-05-15T12:11:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Coronary-No-Reflow-Phenomenon.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Coronary-No-Reflow-Phenomenon.jpg\",\"width\":1202,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/coronary-no-reflow-phenomenon\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Coronary No-Reflow Phenomenon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Coronary No-Reflow Phenomenon - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/","og_locale":"en_US","og_type":"article","og_title":"Coronary No-Reflow Phenomenon - All About Cardiovascular System and Disorders","og_description":"The coronary no-reflow phenomenon is a clinical condition characterized by inadequate myocardial perfusion through a given segment of the coronary circulation without evidence of mechanical obstruction in the epicardial vessel. It is most frequently encountered during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Pathophysiology The etiology is multifactorial and often described [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-05-15T12:11:34+00:00","article_modified_time":"2026-05-15T12:11:37+00:00","og_image":[{"width":1202,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/05\/Coronary-No-Reflow-Phenomenon.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Coronary No-Reflow Phenomenon","datePublished":"2026-05-15T12:11:34+00:00","dateModified":"2026-05-15T12:11:37+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/"},"wordCount":1082,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/05\/Coronary-No-Reflow-Phenomenon.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/","url":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/","name":"Coronary No-Reflow Phenomenon - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/05\/Coronary-No-Reflow-Phenomenon.jpg","datePublished":"2026-05-15T12:11:34+00:00","dateModified":"2026-05-15T12:11:37+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/05\/Coronary-No-Reflow-Phenomenon.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/05\/Coronary-No-Reflow-Phenomenon.jpg","width":1202,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/coronary-no-reflow-phenomenon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Coronary No-Reflow Phenomenon"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=67034"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67034\/revisions"}],"predecessor-version":[{"id":67053,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67034\/revisions\/67053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/67036"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=67034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=67034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=67034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}